Search clinical trials for: SBR759A

Total 4 results

Novartis

Completed

Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients (SBR759)

Chronic Kidney Disease | Hyperphosphatemia

Belgium, Italy
Novartis Pharmaceuticals

Completed

A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis

Chronic Kidney Disease

United States
Novartis Pharmaceuticals

Completed

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis (SBR759)

Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy

Germany, United Kingdom, Italy, Belgium, Sweden, Canada, United States, Australia, Finland, France, Norway, Puerto Rico, Switzerland
Novartis Pharmaceuticals

Completed

Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis (SBR759)

Chronic Kidney Disease

Taiwan, Japan

3

Subscribe